ATE362473T1 - 1,5-disubstituierte 3,4-dihydro-1h-4,5- döpyrimidin-2-on-verbindungen und ihre verwendung in der behandlung von durch csbp/p38 kinase beeinflussten krankheiten - Google Patents

1,5-disubstituierte 3,4-dihydro-1h-4,5- döpyrimidin-2-on-verbindungen und ihre verwendung in der behandlung von durch csbp/p38 kinase beeinflussten krankheiten

Info

Publication number: ATE362473T1
Authority: AT; Austria
Prior art keywords: döpyrimidine; csbp; disubstituted; dihydro; kinase
Prior art date: 2000-03-02

Application number

AT01914625T

Other languages

English (en)

Inventor

Jerry Adams

Jeffrey Boehm

Ralph Hall

John Taggart

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-02

Filing date

2001-03-02

Publication date

2007-06-15

2001-03-02 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2007-06-15 Application granted granted Critical

2007-06-15 Publication of ATE362473T1 publication Critical patent/ATE362473T1/de

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Dermatology (AREA)
Virology (AREA)
Hematology (AREA)
Cardiology (AREA)
Neurology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Tropical Medicine & Parasitology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Endocrinology (AREA)
Psychiatry (AREA)

AT01914625T 2000-03-02 2001-03-02 1,5-disubstituierte 3,4-dihydro-1h-4,5- döpyrimidin-2-on-verbindungen und ihre verwendung in der behandlung von durch csbp/p38 kinase beeinflussten krankheiten ATE362473T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US18641900P	2000-03-02	2000-03-02

Publications (1)

Publication Number	Publication Date
ATE362473T1 true ATE362473T1 (de)	2007-06-15

Family

ID=22684876

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01914625T ATE362473T1 (de)	2000-03-02	2001-03-02	1,5-disubstituierte 3,4-dihydro-1h-4,5- döpyrimidin-2-on-verbindungen und ihre verwendung in der behandlung von durch csbp/p38 kinase beeinflussten krankheiten

Country Status (26)

Country	Link
EP (1)	EP1265900B1 (de)
JP (1)	JP2003525295A (de)
KR (1)	KR100806978B1 (de)
CN (1)	CN100482664C (de)
AR (2)	AR030053A1 (de)
AT (1)	ATE362473T1 (de)
AU (2)	AU3999201A (de)
BR (1)	BR0108715A (de)
CA (1)	CA2402092C (de)
CY (1)	CY1106816T1 (de)
CZ (1)	CZ20022933A3 (de)
DE (1)	DE60128457T2 (de)
DK (1)	DK1265900T3 (de)
ES (1)	ES2287107T3 (de)
HK (1)	HK1052932A1 (de)
HU (1)	HUP0204431A3 (de)
IL (3)	IL151426A0 (de)
MX (1)	MXPA02008588A (de)
MY (1)	MY141144A (de)
NO (1)	NO326409B1 (de)
NZ (1)	NZ520914A (de)
PL (1)	PL358280A1 (de)
PT (1)	PT1265900E (de)
TW (1)	TWI290926B (de)
WO (1)	WO2001064679A1 (de)
ZA (1)	ZA200207017B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE402177T1 (de)	1998-05-26	2008-08-15	Warner Lambert Co	Bicyclische pyrimidine und bicyclische 3,4- dihydropyrimidine als inhibitoren der zellvermehrung
US6858617B2 (en)	1998-05-26	2005-02-22	Smithkline Beecham Corporation	Substituted imidazole compounds
US7053099B1 (en)	1999-11-23	2006-05-30	Smithkline Beecham Corporation	3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
DE60023025T2 (de)	1999-11-23	2006-07-13	Smithkline Beecham Corp.	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
US7053098B1 (en)	1999-11-23	2006-05-30	Smithkline Beecham Corporation	3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ES2372028T3 (es)	2000-10-23	2012-01-13	Glaxosmithkline Llc	Nuevo compuesto de 8h-pirido[2,3-d]pirimidin-7-ona trisustituida para el tratamiento de enfermedades mediadas por la csbp/p38 quinasa.
EP1345603A4 (de) *	2000-12-20	2004-09-08	Merck & Co Inc	(halo-benzo-carbonyl)heterocyclo-kondensierte phenyl-p38-kinase hemmende mittel
GB0124848D0 (en) *	2001-10-16	2001-12-05	Celltech R&D Ltd	Chemical compounds
CN100369898C (zh)	2002-02-12	2008-02-20	史密丝克莱恩比彻姆公司	用作p38抑制剂的烟酰胺衍生物
WO2003068757A1 (en)	2002-02-13	2003-08-21	F. Hoffmann-La Roche Ag	Novel pyridin- and pyrimidin-derivatives
CN1646131A (zh) *	2002-04-19	2005-07-27	史密丝克莱恩比彻姆公司	新化合物
GB0214268D0 (en) *	2002-06-20	2002-07-31	Celltech R&D Ltd	Chemical compounds
PA8577501A1 (es)	2002-07-25	2004-02-07	Warner Lambert Co	Inhibidores de quinasas
GB0218800D0 (en) *	2002-08-13	2002-09-18	Celltech R&D Ltd	Chemical compounds
US7084270B2 (en) *	2002-08-14	2006-08-01	Hoffman-La Roche Inc.	Pyrimido compounds having antiproliferative activity
EP1539121A4 (de)	2002-08-29	2008-08-13	Scios Inc	Verfahren zur forderung der osteogenese
US7112676B2 (en)	2002-11-04	2006-09-26	Hoffmann-La Roche Inc.	Pyrimido compounds having antiproliferative activity
US7384937B2 (en)	2002-11-06	2008-06-10	Bristol-Myers Squibb Co.	Fused heterocyclic compounds and use thereof
US7098332B2 (en)	2002-12-20	2006-08-29	Hoffmann-La Roche Inc.	5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2006522756A (ja)	2003-04-10	2006-10-05	エフ．ホフマン−ラ　ロシュ　アーゲー	ピリミド化合物
US7244441B2 (en)	2003-09-25	2007-07-17	Scios, Inc.	Stents and intra-luminal prostheses containing map kinase inhibitors
ATE457313T1 (de) *	2003-12-23	2010-02-15	Novartis Ag	Bicyclische heterocyclische p-38-kinase- inhibitoren
EP1828186A1 (de) *	2004-12-13	2007-09-05	Sunesis Pharmaceuticals, Inc.	Pyridopyrimidinone, dihydropyrimidopyrimidinone und pteridinone, die sich als raf-kinase-inhibitoren eignen
EP1676574A3 (de)	2004-12-30	2006-07-26	Johnson & Johnson Vision Care, Inc.	Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten
JP5201817B2 (ja) *	2005-10-28	2013-06-05	大塚製薬株式会社	医薬組成物
WO2007147109A2 (en) *	2006-06-16	2007-12-21	Glaxo Group Limited	Novel compounds
WO2007147104A2 (en) *	2006-06-16	2007-12-21	Glaxo Group Limited	Novel compounds
KR101040394B1 (ko) *	2010-05-18	2011-06-09	(주)이성산업	역화 방지 기능을 갖는 야외용 가스 히터
CN102816162B (zh) *	2011-06-10	2016-04-27	中国科学院广州生物医药与健康研究院	嘧啶并嘧啶酮类化合物及其药用组合物和应用
EP2968337B1 (de)	2013-03-15	2021-07-21	Celgene CAR LLC	Heteroarylverbindungen und verwendungen davon
US9321786B2 (en)	2013-03-15	2016-04-26	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
ES2892423T3 (es)	2013-03-15	2022-02-04	Celgene Car Llc	Compuestos de heteroarilo y usos de los mismos
CN106831721B (zh)	2013-10-16	2019-10-22	上海璎黎药业有限公司	稠合杂环化合物、其制备方法、药物组合物和用途
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3078232A1 (en)	2017-10-05	2019-04-11	Fulcrum Therapeutics, Inc.	Use of p38 inhibitors to reduce expression of dux4
TW202327600A (zh)	2021-10-20	2023-07-16	香港商英科智能有限公司	甲硫胺酸腺苷轉移酶２ａ（ｍａｔ２ａ）抑制劑及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60226882A (ja) *	1984-04-24	1985-11-12	Nippon Zoki Pharmaceut Co Ltd	新規ピリミドピリミジン誘導体
CZ292806B6 (cs) *	1996-08-06	2003-12-17	Pfizer Inc.	Pyrido- nebo pyrimido-6,6- nebo -6,7-bicyklické deriváty, farmaceutické kompozice na jejich bázi
ATE402177T1 (de) *	1998-05-26	2008-08-15	Warner Lambert Co	Bicyclische pyrimidine und bicyclische 3,4- dihydropyrimidine als inhibitoren der zellvermehrung
AU4429799A (en) *	1998-06-12	1999-12-30	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
EP1123295B1 (de) *	1998-10-23	2004-09-29	F. Hoffmann-La Roche Ag	Bicyclische stickstoffheteroaryl verbindungen

2001
- 2001-02-28 MY MYPI20010900A patent/MY141144A/en unknown
- 2001-02-28 AR ARP010100940A patent/AR030053A1/es unknown
- 2001-03-02 WO PCT/US2001/006688 patent/WO2001064679A1/en active Application Filing
- 2001-03-02 KR KR1020027011408A patent/KR100806978B1/ko not_active IP Right Cessation
- 2001-03-02 ES ES01914625T patent/ES2287107T3/es not_active Expired - Lifetime
- 2001-03-02 TW TW090104783A patent/TWI290926B/zh not_active IP Right Cessation
- 2001-03-02 AU AU3999201A patent/AU3999201A/xx active Pending
- 2001-03-02 IL IL15142601A patent/IL151426A0/xx active IP Right Grant
- 2001-03-02 PL PL01358280A patent/PL358280A1/xx not_active Application Discontinuation
- 2001-03-02 CA CA2402092A patent/CA2402092C/en not_active Expired - Fee Related
- 2001-03-02 AT AT01914625T patent/ATE362473T1/de active
- 2001-03-02 EP EP01914625A patent/EP1265900B1/de not_active Expired - Lifetime
- 2001-03-02 BR BR0108715-0A patent/BR0108715A/pt not_active Application Discontinuation
- 2001-03-02 HU HU0204431A patent/HUP0204431A3/hu unknown
- 2001-03-02 MX MXPA02008588A patent/MXPA02008588A/es active IP Right Grant
- 2001-03-02 AU AU2001239992A patent/AU2001239992B2/en not_active Ceased
- 2001-03-02 JP JP2001564176A patent/JP2003525295A/ja active Pending
- 2001-03-02 PT PT01914625T patent/PT1265900E/pt unknown
- 2001-03-02 DE DE60128457T patent/DE60128457T2/de not_active Expired - Lifetime
- 2001-03-02 DK DK01914625T patent/DK1265900T3/da active
- 2001-03-02 CN CNB018076866A patent/CN100482664C/zh not_active Expired - Fee Related
- 2001-03-02 NZ NZ520914A patent/NZ520914A/en not_active IP Right Cessation
- 2001-03-02 CZ CZ20022933A patent/CZ20022933A3/cs unknown
2002
- 2002-08-22 IL IL151426A patent/IL151426A/en not_active IP Right Cessation
- 2002-08-30 NO NO20024134A patent/NO326409B1/no not_active IP Right Cessation
- 2002-09-02 ZA ZA200207017A patent/ZA200207017B/en unknown
2003
- 2003-05-07 AR ARP030101602A patent/AR040075A2/es unknown
- 2003-05-27 HK HK03103782A patent/HK1052932A1/xx not_active IP Right Cessation
2007
- 2007-08-13 CY CY20071101080T patent/CY1106816T1/el unknown
2008
- 2008-02-28 IL IL189865A patent/IL189865A0/en unknown

Also Published As

Publication number	Publication date
HUP0204431A1 (hu)	2003-04-28
CN1422273A (zh)	2003-06-04
KR20020082858A (ko)	2002-10-31
EP1265900A4 (de)	2004-11-10
CN100482664C (zh)	2009-04-29
DK1265900T3 (da)	2007-09-24
KR100806978B1 (ko)	2008-02-25
DE60128457T2 (de)	2008-01-17
CA2402092A1 (en)	2001-09-07
CY1106816T1 (el)	2012-01-25
PL358280A1 (en)	2004-08-09
CA2402092C (en)	2012-01-24
BR0108715A (pt)	2004-04-27
NO20024134L (no)	2002-10-24
AR030053A1 (es)	2003-08-13
WO2001064679A1 (en)	2001-09-07
ZA200207017B (en)	2004-02-26
DE60128457D1 (de)	2007-06-28
PT1265900E (pt)	2007-08-22
TWI290926B (en)	2007-12-11
HK1052932A1 (en)	2003-10-03
MXPA02008588A (es)	2003-02-24
CZ20022933A3 (cs)	2003-02-12
IL151426A (en)	2011-01-31
IL189865A0 (en)	2008-08-07
AU3999201A (en)	2001-09-12
NO326409B1 (no)	2008-12-01
EP1265900B1 (de)	2007-05-16
NZ520914A (en)	2004-03-26
JP2003525295A (ja)	2003-08-26
NO20024134D0 (no)	2002-08-30
EP1265900A1 (de)	2002-12-18
AU2001239992B2 (en)	2005-09-01
IL151426A0 (en)	2003-04-10
HUP0204431A3 (en)	2006-01-30
ES2287107T3 (es)	2007-12-16
AR040075A2 (es)	2005-03-16
MY141144A (en)	2010-03-15

Publication	Publication Date	Title
ATE362473T1 (de)	2007-06-15	1,5-disubstituierte 3,4-dihydro-1h-4,5- döpyrimidin-2-on-verbindungen und ihre verwendung in der behandlung von durch csbp/p38 kinase beeinflussten krankheiten
ATE345792T1 (de)	2006-12-15	Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer- krankheit
DE602004015269D1 (de)	2008-09-04	Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten.
DE60234116D1 (de)	2009-12-03	Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems
ATE327757T1 (de)	2006-06-15	Verwendung von flibanserin bei der behandung von störungen des sexuellen verlangens
DE60222671D1 (de)	2007-11-08	Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
DE60121294D1 (de)	2006-08-17	Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung
DE69910831D1 (de)	2003-10-02	Epothilonderivate und ihre verwendung als antitumormittel
ATE448238T1 (de)	2009-11-15	3-beta-d-ribofuranosylthiazolo(4,5- delta)pyridimin-nucleoside und ihre verwendung
ATE318821T1 (de)	2006-03-15	Pyranoindazole und ihre verwendung in der glaukombehandlung
ATE421954T1 (de)	2009-02-15	Heteroaryl-hexansäureamid-derivate, ihre herstellung und ihre verwendung als selektive inhibitoren der bindung von mip-1-alpha an seinen ccr1 rezeptor
ATE415392T1 (de)	2008-12-15	Pyrimidinonderivate und deren verwendung bei der behandlung von atherosklerose
DE60203197D1 (de)	2005-04-14	4-(oxadiazol-3-yl)-1,4-diazabizyklo[3.2.2]-nonanderivate, ihre herstellung und therapeutische verwendung
ATE424837T1 (de)	2009-03-15	Verwendung von lanthan bei der behandlung von knochenerkrankungen
DE50301941D1 (de)	2006-01-19	Derivate-1h-pyrazolo (3, 4-b) -5-(4-pyridinyl)-4-pyrimidinamins und ihre verwendung als guanylatcyclase-stimulatoren
ATE420642T1 (de)	2009-01-15	Neue formulierungen und ihre verwendung
ATE265454T1 (de)	2004-05-15	Phenyloxazol-1,4-diazabicyclo(3.2.2)nonanderiva e,ihre herstellung und ihre therapeutische verwendung
DE60204755D1 (de)	2005-07-28	"3,7-diazabicyclo(3.3.0)octane und deren verwendung bei der behandlung von herzrhythmusstörungen"
DE60130365D1 (de)	2007-10-18	Die Verwendung von Rosiglitazon zur Behandlung von psychiatrischen Erkrankungen.
DE50114605D1 (de)	2009-02-05	No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE247109T1 (de)	2003-08-15	Substituierte benzoylisoxazole und ihre verwendung als herbizide
ATE367160T1 (de)	2007-08-15	Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
EE200300527A (et)	2004-02-16	4-(fenüülpiperidiin-4-ülideenmetüül)bensamiidi derivaadid ja nende kasutamine valu, ärevuse või seedetrakti häirete raviks
DE69106199D1 (de)	1995-02-09	Heterocyclische Acetonitrile und ihre Verwendung als Fungizide.
DE50313185D1 (de)	2010-11-25	2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva

Legal Events

Date	Code	Title	Description
2007-11-15	UEP	Publication of translation of european patent specification	Ref document number: 1265900 Country of ref document: EP

Date

Code

Title

Description

2007-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1265900

Country of ref document: EP